LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration Small Mol Conc Unit LJP Library Plate Replicate Assay Well Timepoint Timepoint Unit Total Cell Count Before Treatment Total Cell Count After Treatment Total Control Cell Count Relative Cell Count Relative Growth Rate After Treatment
SK-BR-3 Lapatinib
0.37
uM
LJP6
 3
M22
 72
hr
 1476 1596 3694 0.4321 0.0538
SK-BR-3 LDN-193189
0.37
uM
LJP5
 1
G04
 72
hr
 1476 4097 3694 1.1091 1.1817
SK-BR-3 LDN-193189
0.37
uM
LJP5
 2
G04
 72
hr
 1476 4210 3694 1.1397 1.2327
SK-BR-3 LDN-193189
0.37
uM
LJP5
 3
G04
 72
hr
 1476 4240 3694 1.1478 1.2462
SK-BR-3 Linifanib
0.37
uM
LJP6
 1
J10
 72
hr
 1476 3502 3694 0.9480 0.9134
SK-BR-3 Linifanib
0.37
uM
LJP6
 2
J10
 72
hr
 1476 4144 3694 1.1218 1.2029
SK-BR-3 Linifanib
0.37
uM
LJP6
 3
J10
 72
hr
 1476 4166 3694 1.1278 1.2128
SK-BR-3 Linsitinib
0.37
uM
LJP5
 1
O22
 72
hr
 1476 3053 3694 0.8265 0.7109
SK-BR-3 Linsitinib
0.37
uM
LJP5
 2
O22
 72
hr
 1476 3053 3694 0.8265 0.7109
SK-BR-3 Linsitinib
0.37
uM
LJP5
 3
O22
 72
hr
 1476 3191 3694 0.8638 0.7731
SK-BR-3 Mitoxantrone
0.37
uM
LJP5
 1
C22
 72
hr
 1476 1631 3694 0.4415 0.0696
SK-BR-3 Mitoxantrone
0.37
uM
LJP5
 2
C22
 72
hr
 1476 1630 3694 0.4413 0.0691
SK-BR-3 Mitoxantrone
0.37
uM
LJP5
 3
C22
 72
hr
 1476 1548 3694 0.4191 0.0321
SK-BR-3 Mitoxantrone
0.37
uM
LJP6
 1
C22
 72
hr
 1476 1431 3694 0.3874 -0.0206
SK-BR-3 Mitoxantrone
0.37
uM
LJP6
 2
C22
 72
hr
 1476 1697 3694 0.4594 0.0993
SK-BR-3 Mitoxantrone
0.37
uM
LJP6
 3
C22
 72
hr
 1476 1541 3694 0.4172 0.0290
SK-BR-3 MK2206
0.37
uM
LJP6
 1
F04
 72
hr
 1476 2518 3694 0.6816 0.4696
SK-BR-3 MK2206
0.37
uM
LJP6
 2
F04
 72
hr
 1476 2522 3694 0.6827 0.4714
SK-BR-3 MK2206
0.37
uM
LJP6
 3
F04
 72
hr
 1476 2632 3694 0.7125 0.5210
SK-BR-3 Neratinib
0.37
uM
LJP5
 1
A16
 72
hr
 1476 1432 3694 0.3877 -0.0202
SK-BR-3 Neratinib
0.37
uM
LJP5
 2
A16
 72
hr
 1476 1346 3694 0.3644 -0.0590
SK-BR-3 Neratinib
0.37
uM
LJP5
 3
A16
 72
hr
 1476 1243 3694 0.3365 -0.1054
SK-BR-3 Nilotinib
0.37
uM
LJP5
 1
N16
 72
hr
 1476 4041 3694 1.0939 1.1565
SK-BR-3 Nilotinib
0.37
uM
LJP5
 2
N16
 72
hr
 1476 4034 3694 1.0920 1.1533
SK-BR-3 Nilotinib
0.37
uM
LJP5
 3
N16
 72
hr
 1476 4187 3694 1.1334 1.2223